What the warning says
Section 5.2 says that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing forms, has been seen with GLP-1 receptor agonists, Ozempic® among them. Hemorrhagic and necrotizing describe severe forms with bleeding or tissue death in the pancreas. After Ozempic® is started, clinicians are asked to watch for persistent or severe abdominal pain, sometimes spreading to the back, with or without nausea or vomiting, and to stop Ozempic® if pancreatitis is suspected [1].
Europe adds that semaglutide should not be restarted if pancreatitis is confirmed and that caution is needed in people with a history of pancreatitis. Canada says the same about restarting and asks prescribers to consider other diabetes treatments for people with a past episode [2][3].
Confirmed cases in the trials
Trial cases were confirmed by adjudication, an independent expert review of each suspected case. Rates per 100 patient-years account for how long people were treated [1][3].
| Trial set and document | Ozempic® | Comparison |
|---|---|---|
| Glycemic control trials, US label [1] | 7 cases; 0.3 per 100 patient-years | 3 cases; 0.2 per 100 patient-years (comparators) |
| Same trials, Canadian monograph [3] | Also 1 confirmed case of chronic pancreatitis | The 3 comparator cases were on another GLP-1 medicine; none on placebo or other drug classes |
| SUSTAIN 6, 2-year cardiovascular trial, Canadian monograph [3] | 8 cases; 0.27 per 100 patient-years | 10 cases; 0.33 per 100 patient-years (placebo) |
| Phase 3a pool and cardiovascular trial, European SmPC [2] | 0.3% (phase 3a); 0.5% (cardiovascular trial) | 0.2% (comparator); 0.6% (placebo) |
Pancreatic enzyme changes
In the US placebo-controlled trials, people on Ozempic® had an average increase from baseline of 13% in amylase and 22% in lipase, two enzymes made by the pancreas; placebo users had no such increase [1]. Canada reports raised lipase as an adverse reaction in 9.0% on both doses against 6.4% on comparators, and raised amylase in 3.4% and 3.0% against 2.6% [3]. Europe classes both as common [2].
None of the documents ties these average rises to individual cases of pancreatitis, so a blood test result is something to discuss with the clinician who ordered it.
Reports after approval
Section 6.2 lists acute pancreatitis and necrotizing pancreatitis, sometimes resulting in death, among reactions reported after semaglutide reached the market. These are voluntary reports from an unknown number of users, so the label notes that their frequency cannot always be reliably estimated and a causal link cannot always be established [1]. Canada lists pancreatitis among its post-market reports too [3].
What research shows
A meta-analysis of 43 randomised trials lasting at least a year, in people with type 2 diabetes on GLP-1 medicines including semaglutide, found no clear association with pancreatitis (odds ratio 1.24, confidence interval 0.94 to 1.64) [4]. A 2025 meta-analysis of 55 placebo-controlled trials with 106,395 participants reached a similar conclusion: GLP-1 medicines probably have little or no effect on pancreatitis risk [5].
A 2023 US insurance-claims study of people without diabetes who started semaglutide or liraglutide for weight loss found a higher pancreatitis risk than with bupropion-naltrexone (adjusted hazard ratio 9.09). The confidence interval was very wide (1.25 to 66.0), only 2 of the cases were in the 613 semaglutide users, and the study could not confirm why each medicine was prescribed [6]. Randomised trials and claims studies answer different questions, so neither settles the matter alone.
Why it may happen
What the label supports: acute pancreatitis has been observed in people on GLP-1 receptor agonists, and pancreatic enzymes rose on average in Ozempic® trials [1].
What is not established: none of the official documents explains how a GLP-1 medicine might trigger pancreatitis, and the trial meta-analyses did not find a clear rise [1][4][5]. Gallstones, which GLP-1 medicines do increase, are the most common cause of acute pancreatitis, but the documents do not say whether that explains any Ozempic® cases [5][8].
General background: MedlinePlus explains that acute pancreatitis happens when digestive enzymes become active inside the pancreas and start damaging its own tissue [8].
Other causes of pancreatitis
- Gallstones, the most common cause of acute pancreatitis [7][8].
- Heavy alcohol use, which MedlinePlus links to 17% to 25% of US cases [8].
- Very high blood triglycerides, high blood calcium and genetic conditions [7][8].
- Certain medicines, including estrogens, corticosteroids, thiazides and azathioprine [8].
- Injury to the abdomen, infections such as mumps, and procedures on the bile and pancreatic ducts [7][8].
What helps
There is no home treatment for suspected pancreatitis. The Medication Guide’s instruction is to stop Ozempic® and call your healthcare provider right away, and section 17 tells prescribers to give patients that instruction [1]. NIDDK says people with acute pancreatitis usually look and feel seriously ill and need to see a doctor right away, and MedlinePlus notes that treatment often requires a hospital stay [7][8].
Before starting, the Medication Guide asks you to tell your healthcare provider about any current or past pancreas problem [1]. Whether to restart Ozempic® after an episode is your prescriber’s decision; Europe and Canada say it should not be restarted if pancreatitis is confirmed [2][3].
Information your clinician will want
When you call, it helps to say when the pain began, whether it has been constant or comes in waves, whether it spreads to your back, whether you have vomited and how often, and whether you can keep fluids down. Mention your current Ozempic® dose, the date of your last injection and of your last dose increase, every other medicine you take, alcohol use and any earlier gallstones or pancreas problems.
Ozempic® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Severe stomach pain that will not go away, with or without vomiting, possibly felt from the abdomen to the back | Stop Ozempic® and call your healthcare provider right away | Emergency | Medication Guide and section 17 [1] |
| Severe or worsening belly pain with fever or chills, a fast heartbeat, shortness of breath or yellowing | Seek care right away | Emergency | NIDDK [7] |
| Intense, constant abdominal pain | Your healthcare provider | Today | MedlinePlus [8] |
| A raised amylase or lipase result on a routine blood test, without symptoms | The clinician who ordered the test | At your next appointment | Section 6.1 [1] |
| A past episode of pancreatitis, before starting Ozempic® | Your prescriber | At your next appointment | Medication Guide [1] and Canadian monograph [3] |
